Search research articles
Contact Us
Filters
Showing results (71-80 of 160) with videos related to
Page
of 16
Sort By:
Blood Cancer Journal
|
November 25, 2025
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide
Wei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek, et al.
Cancer
|
September 26, 2019
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
Kiran Naqvi, Elias Jabbour, Jeffrey Skinner, et al.
American Journal of Hematology
|
November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression
Elias Jabbour, Johannes Düll, Musa Yilmaz, et al.
American Journal of Hematology
|
September 2, 2022
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis
Elias Jabbour, Koji Sasaki, Fadi G Haddad, et al.
American Journal of Hematology
|
March 31, 2022
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors
Fadi G Haddad, Koji Sasaki, Ghayas C Issa, et al.
Cancer
|
December 7, 2018
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes
Prajwal C Boddu, Tapan M Kadia, Guillermo Garcia-Manero, et al.
Leukemia Research
|
April 19, 2025
Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome
Julie S Braish, Guillermo Montalban-Bravo, Farhad Ravandi, et al.
Blood Cancer Journal
|
June 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia
Elias Jabbour, Caitlin R Rausch, Hannah Goulart, et al.
Blood Cancer Journal
|
January 18, 2019
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
Musa Yilmaz, Feng Wang, Sanam Loghavi, et al.
Blood Cancer Journal
|
May 6, 2020
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype
Bachar Samra, Guillaume Richard-Carpentier, Tapan M Kadia, et al.
Page
of 16
Search research articles
Search
Showing results (71-80 of 160) with videos related to
Sort By:
Page
of 16
Blood Cancer Journal
|
November 25, 2025
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide
Wei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek, et al.
Cancer
|
September 26, 2019
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
Kiran Naqvi, Elias Jabbour, Jeffrey Skinner, et al.
American Journal of Hematology
|
November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression
Elias Jabbour, Johannes Düll, Musa Yilmaz, et al.
American Journal of Hematology
|
September 2, 2022
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis
Elias Jabbour, Koji Sasaki, Fadi G Haddad, et al.
American Journal of Hematology
|
March 31, 2022
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors
Fadi G Haddad, Koji Sasaki, Ghayas C Issa, et al.
Cancer
|
December 7, 2018
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes
Prajwal C Boddu, Tapan M Kadia, Guillermo Garcia-Manero, et al.
Leukemia Research
|
April 19, 2025
Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome
Julie S Braish, Guillermo Montalban-Bravo, Farhad Ravandi, et al.
Blood Cancer Journal
|
June 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia
Elias Jabbour, Caitlin R Rausch, Hannah Goulart, et al.
Blood Cancer Journal
|
January 18, 2019
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
Musa Yilmaz, Feng Wang, Sanam Loghavi, et al.
Blood Cancer Journal
|
May 6, 2020
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype
Bachar Samra, Guillaume Richard-Carpentier, Tapan M Kadia, et al.
Page
of 16